Genetic Technologies (CHIA:GTG) - Hisse Senedi Fiyatı, Haberler ve Analizler

GTG Stoklara Genel Bakış

GTG temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Hisse senetleri oldukça likit değildir

Kazançlar son 5 yılda yılda 16.6% oranında azaldı

Anlamlı bir piyasa değeri yok ( A$6M )

Hissedarlar geçen yıl sulandırıldı

Genetic Technologies Limited Rakipler

Memphasys

ASX:MEM

AU$8.7m

OncoSil Medical

ASX:OSL

AU$31.4m

Cryosite

ASX:CTE

AU$43.7m

Proteomics International Laboratories

ASX:PIQ

AU$85.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Genetic Technologies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$0.038
52 Haftanın En Yüksek Seviyesi	AU$0.25
52 Haftanın En Düşük Seviyesi	AU$0.038
Beta	0.48
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-84.80%
33 Yıllık Değişim	-93.67%
5 Yıllık Değişim	-90.50%
Halka arzdan bu yana değişim	-98.42%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	GTG	AU Life Sciences	AU Pazar
7D	0%	-6.0%	0.9%
1Y	-84.8%	8.8%	17.7%

Getiri vs. Endüstri: GTG geçen yıl % 8.8 oranında getiri sağlayan Australian Life Sciences sektörünün gerisinde kaldı.

Getiri vs Piyasa: GTG geçen yıl % 17.7 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is GTG's price volatile compared to industry and market?
GTG volatility
GTG Average Weekly Movement	n/a
Life Sciences Industry Average Movement	11.2%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.3%

İstikrarlı Hisse Senedi Fiyatı: GTG hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: GTG 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1987	55	Simon Morriss	genetype.com

Bir moleküler tanı şirketi olan Genetic Technologies Limited, Amerika, Kanada, Avrupa, Orta Doğu, Afrika, Latin Amerika ve Asya Pasifik'te doktorların insanların sağlığını yönetmelerine yardımcı olmak için öngörücü genetik testler ve risk değerlendirme araçları sunmaktadır. Şirket EasyDNA, AffinityDNA ve GeneType/Corporate segmentleri aracılığıyla faaliyet göstermektedir. Kalıtsal olmayan meme kanseri için klinik olarak onaylanmış bir risk değerlendirme testi olan BREVAGenplus'ı sunmaktadır.

Genetic Technologies Limited Temel Bilgiler Özeti

Genetic Technologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
GTG temel i̇stati̇sti̇kler
Piyasa değeri	AU$5.67m
Kazançlar(TTM)	-AU$12.02m
Gelir(TTM)	AU$9.67m

0.6x

P/S Oranı

-0.5x

F/K Oranı

GTG aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
GTG gelir tablosu (TTM)
Gelir	AU$9.67m
Gelir Maliyeti	AU$3.76m
Brüt Kâr	AU$5.91m
Diğer Giderler	AU$17.93m
Kazançlar	-AU$12.02m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.083
Brüt Marj	61.12%
Net Kâr Marjı	-124.24%
Borç/Özkaynak Oranı	35.2%

GTG uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

GTG Stoklara Genel Bakış

Risk Analizi

Genetic Technologies Limited Rakipler

ASX:MEM

AU$8.7m

ASX:OSL

AU$31.4m

ASX:CTE

AU$43.7m

ASX:PIQ

AU$85.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Recent updates

Full year 2024 earnings released: AU$0.091 loss per share (vs AU$0.12 loss in FY 2023)

Genetic Technologies Limited Announces Global Launch of GeneType on Wholly Owned EasyDNA Platform

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of AUD 1.71026 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of AUD 3.997793 million.

Genetic Technologies Limited Appoints Mark Ziirsen as Chief Financial Officer

Genetic Technologies Limited Announces Resignation of Kathryn Andrews as CFO

Genetic Technologies Limited Share the Power of the geneType Test in Identifying Risk and Improving the Health of Populations Worldwide

New major risk - Revenue and earnings growth

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Shareholder dilution

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $11.2056 million.

Genetic Technologies Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston

Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare

Independent Non-Executive Chairman recently bought AU$80k worth of stock

New major risk - Financial position

Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer

Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Market cap size

Genetic Technologies Limited, Annual General Meeting, Nov 22, 2023

Genetic Technologies Limited Announces the Expanded GeneType Multi-Risk Test Is Now Available to Order in Australia

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Genetic Technologies Limited Announces Publication Highlights Genetype’S Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Genetic Technologies Limited Provides Further Update on Comprehensive Risk Test for Breast & Ovarian Cancer

Genetic Technologies Limited to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Non-Independent Non-Executive Director recently sold AU$77k worth of stock

Genetic Technologies Limited Published in Plus One for Cvd & Type 2 Diabetes

Genetic Technologies Limited, Annual General Meeting, Nov 28, 2022

Genetic Technologies Limited Appoints Tony Di Pietro as Chief Financial Officer

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2021)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of eCommerce Business and Distribution Rights of AffinityDNA from Affinity DNA Limited.

Genetic Technologies Limited Announces Resignation of Michael Tonroe as Company Secretary

Genetic Technologies Limited Commences Initial Implementation of its geneType Risk Assessment Test at 16 Medical Practices Across the East Coast of Australia

Genetic Technologies Limited Announces the Completion of an Independently Developed and Validated Customisable Budget Impact Model

Genetic Technologies Limited (ASX:GTG) entered into an agreement to acquire eCommerce Business and Distribution Rights of AffinityDNA from Affinity Dna Limited for £0.555 million

Genetic Technologies Limited Announces GeneType Multi-Test Approves for Commercial Release

High number of new and inexperienced directors

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2020)

Genetic Technologies Limited (ASX:GTG) completed the acquisition of General Genetics Corporation from BelHealth Investment Fund, L.P. managed by BelHealth Investment Partners, LLC.

Company Secretary Justyn Stedwell has left the company

Genetic Technologies Limited Confirms the Launch of GTG's Covid-19 Serious Disease Risk Test (`Covid-19 Risk Test') by US Based Infinity Biologix LLC

Genetic Technologies Limited Provides COVID-19 Risk Test Launch Update

Genetic Technologies Limited Signs 3-Year US Licence Agreement for COVID Risk Test

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $6.5625 million.

Genetic Technologies Limited Provides Update on Its COVID-19 Disease Severity Risk Test and Expansion into Germline Testing

Genetic Technologies Limited Announces Management Changes

Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

Genetic Technologies Limited, Annual General Meeting, Dec 10, 2020

Genetic Technologies Limited to Report Q4, 2020 Results on Oct 30, 2020

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Provides Update on COVID-19 Risk Test

Full year earnings released - AU$0.0015 loss per share

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Regains Compliance with Nasdaq Stockholders Equity Requirement

Full year earnings released - AU$0.0015 loss per share

Genetic Technologies Limited has completed a Follow-on Equity Offering in the amount of $5.125 million.

Hissedar Getirileri

Fiyat Oynaklığı